Sponsor Dossier
Sanofi-Aventis
Sponsor Dossier for Sanofi-Aventis. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ACT-HIB
- Brand: ADACEL
- Brand: ADENOCOR
- Brand: ADENOSCAN
- Brand: ALDURAZYME
- Brand: ALPROLIX
- Brand: ALTUVIIIO
- Brand: AMDARONE
- Device (sponsor): Medication transfer set
- Device (sponsor): Specimen receptacle IVDs
- Device (sponsor): Medication transfer set
- Device (sponsor): Basic insulin pen, replaceable-cartridge
- Device (sponsor): Basic insulin pen, replaceable-cartridge
- Device (sponsor): SYNVISC-ONE (Hylan G-F 20) - Synovial fluid supplementation substance
- Device (sponsor): SYNVISC - Synovial fluid supplementation substance
- Device (sponsor): Dispenser, medication, liquid
About
Sanofi-Aventis is an Australian Private Company with ABN 31008558807, registered in New South Wales and currently active.
Portfolio
Sanofi-Aventis has 102 brands on the ARTG, of which 94 are indexable. The company has 93 brands with Product Information on file, 24 brands with at least one PBS-listed item, 27 brands with PBAC outcome records, and 9 brands with AusPAR records.
Therapeutic focus —
Neurology: 17 brands — Cardiology: 15 brands — Infectious Disease: 14 brands — Endocrinology: 8 brands — Oncology: 8 brands — Immunology: 8 brands — Pain Management: 8 brands — Haematology: 6 brands — Rare Disease: 5 brands — Ophthalmology: 3 brands — Pain & Anaesthesia: 2 brands — Respiratory: 2 brands — Renal: 2 brands — Psychiatry: 1 brand — Complementary Medicine: 1 brand — Urology: 1 brand — Reproductive Health: 1 brand
PBS footprint
Sanofi-Aventis has 24 brands with at least one PBS-listed item, with the portfolio most recently touching the PBS schedule on 1 May 2026.
Regulatory activity
The company's latest PBAC outcome was dated 1 December 2025, with 27 brands holding PBAC outcome records. The most recent AusPAR was issued on 22 November 2023, with 9 brands holding AusPAR records.